Latest Conference Articles

Primary care will require a focus on individual and community health in the post coronavirus disease 2019 (COVID-19) era, according to a session presented on Thursday during the Pharmacy Quality Alliance (PQA) 2020 Annual Meeting.

Awards honor an individual and community pharmacy for innovative and pioneering practices.

Medication therapy problem category framework is the tool used to collect and evaluate medication-related issues

The impact of COVID-19 on pharmacy has been significant in the short-term, and recent developments have shown that there is opportunity for that to translate into long-term changes for the industry.

At the PQA 2020 Annual Meeting on Thursday, speakers discussed some of the drivers of medication adherence in community pharmacy.

Awards honor excellence and improvements in overall star ratings and PQA medication measures.

Pharmacy Quality Solutions Annual Trend Report focuses on questions around consumer perceptions and behaviors.

In order to curb the opioid epidemic among employees, companies need to begin by identifying who is at risk.

In outpatient breast cancer clinics, oral chemotherapies are becoming more common for various malignancies, but hematologic and non-hematologic toxicities can cause challenges for patients.

Oral oncolytics has become increasingly common as treatment for patients with cancer over the past several years.

The objective of the study was to develop an education program that increased confidence and knowledge of pharmacists managing CDK4/6 inhibitors.

PTCE will offer 15 virtual CE sessions throughout May.

In the oral chemotherapy setting, pharmacist care exceeded patients’ expectations and helped manage and avoid adverse events (AEs).

In a lecture at the virtual Community Oncology Conference 2020, Christine Roussel discussed some clinical considerations for the use of medical cannabis in patients with cancer.

There are a variety of interventions that can be used to improve survival after a patient reports cancer toxicity following treatment.

An expert panel at the Community Oncology Conference 2020 discussed how COVID-19 is changing the future of community oncology.

Alexander Spira, MD, PhD, FACP, discussed how there are many types of malignancies when it comes to lung cancer, and we need to set this paradigm for our patients in the future.

The era of social distancing will likely leave a lasting impression on telehealth services, as HCPs quickly learn to incorporate it as a valuable tool and adapt to changes.

The current state of oncology is shaping challenges for the future specifically in the areas of telehealth, home infusions, and a surge of new patients that have not been to oncology clinics yet.

Experts discuss what their teams have learned throughout the COVID-19 pandemic, during the COA virtual conference.

Solving challenges of the current system is vital to spreading clinical trials into community clinics, which may be increasingly important.

In preliminary data from the trial evaluating dostarlimab, the results demonstrated that the clinical activity in patients with previously treated recurrent or advanced mismatch repair (MMR)-deficient endometrial cancer had an acceptable safety profile.

Treatment of ovarian cancer with poly (ADP-ribose) polymerase (PARP) inhibitors has a high out-of-pocket cost for patients, with substantial variation among them, according to a study.

An interview with Debra Richardson, MD, examined the phase 2 study that included niraparib with bevacizumab for patients with either a complete or partial response after upfront chemotherapy for advanced ovarian cancer.

In a population of patients newly diagnosed with ovarian cancer, researchers demonstrated that therapy is well tolerated among both patients who are BRCA-positive and -negative.

The combination of olaparib plus bevacizumab lead to a potentially meaningful improvement in progression-free survival versus olaparib alone in women with BRCA-mutated newly diagnosed ovarian cancer.

The JAVELIN trial is a randomized, open-label, phase 3 trial comparing avelumab in combination with chemotherapy versus chemotherapy alone.

In patients with BRCA wild type carcinomas, treatment with veliparib was beneficial even at low homologous recombination deficiency scores compared with carboplatin and paclitaxel.

The addition of pazoparib to gemcitabine enhances anti-tumor activity, particularly for patients with platinum-resistant disease who derived the most benefit from combination therapy, even in the setting of receiving prior bevacizumab.

The JAVELIN trial is a randomized, open-label, phase 3 trial comparing avelumab in combination with chemotherapy versus chemotherapy alone.